These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 2010558)

  • 41. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botanicals as "new" drugs: US development.
    Hoffman FA
    Epilepsy Behav; 2015 Nov; 52(Pt B):338-43. PubMed ID: 26319115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncology drug review process.
    Farrell AT; Pazdur R
    J Natl Compr Canc Netw; 2003 Jan; 1(1):109-13. PubMed ID: 19764154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of US Food and Drug Administration review intervals for drugs approved during the period 1997-2002.
    Kros JF; Qian J
    Am J Ther; 2004; 11(5):337-43. PubMed ID: 15356429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor.
    Drugs R D; 2005; 6(2):111-5. PubMed ID: 15777104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
    Barrio JR; Marcus CS; Hung JC; Keppler JS
    Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyaluronidase (Vitrase)--ISTA: hyaluronidase--ISTA pharmaceuticals.
    Drugs R D; 2003; 4(3):194-7. PubMed ID: 12757408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The drug lag issue: a 20-year review of China.
    Li X; Yang Y
    Invest New Drugs; 2021 Oct; 39(5):1389-1398. PubMed ID: 33928468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The investigative process for new drugs.
    Nicklas RA
    Ann Allergy; 1989 Dec; 63(6 Pt 2):598-600. PubMed ID: 2688499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.
    Drugs R D; 2004; 5(6):339-42. PubMed ID: 15563237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
    Dheman N; Mahoney N; Cox EM; Farley JJ; Amini T; Lanthier ML
    Clin Infect Dis; 2021 Dec; 73(11):e4444-e4450. PubMed ID: 32584952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
    Freije I; Lamouche S; Tanguay M
    Ther Innov Regul Sci; 2020 Jan; 54(1):128-138. PubMed ID: 32008242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drug development in the United States from 1963 to 1990.
    DiMasi JA; Bryant NR; Lasagna L
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):471-86. PubMed ID: 1934860
    [No Abstract]   [Full Text] [Related]  

  • 59. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exisulind Cell Pathways.
    Griffiths GJ
    Curr Opin Investig Drugs; 2000 Nov; 1(3):386-91. PubMed ID: 11249724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.